Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
83.61
+0.57 (+0.69%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gilead Sciences
< Previous
1
2
3
4
5
6
7
8
9
...
50
51
Next >
Key Takeaways From Gilead Sciences Analyst Ratings
July 01, 2024
Via
Benzinga
3 Magnificent Stocks Retirees Can Buy and Hold Forever
July 01, 2024
These stocks could be ideal for investors in their golden years.
Via
The Motley Fool
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields
June 28, 2024
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
June 25, 2024
Via
Benzinga
Gilead Sciences's Options Frenzy: What You Need to Know
June 24, 2024
Via
Benzinga
7 Dividend Stocks to Buy Now: June 2024
June 23, 2024
These dividend stocks to buy now will reward investors with income now and growth as the market breadth expands.
Via
InvestorPlace
$100 Invested In This Stock 20 Years Ago Would Be Worth $800 Today
June 19, 2024
Via
Benzinga
What 8 Analyst Ratings Have To Say About Gilead Sciences
June 14, 2024
Via
Benzinga
DraftKings And Dell Were Among The 10 Biggest Large Cap Stock Gainers Last Week (June 16-June 22): Are These In Your Portfolio?
June 23, 2024
Top performers last week were SRPT (+29.50%), SIRI (+16.73%), TOST (+15.57%), GILD (+12.62%), CHWY (+10.59%), ACN (+9.80%), DKNG (+9.69%), DELL (+8.19%), ADSK (+7.99%), and GFI (+7.15%).
Via
Benzinga
MarketBeat Week in Review – 6/17 - 6/21
June 22, 2024
Markets were calmer this week, with the Dow index posting the biggest gains, but it's too early to tell if this is the start of a broader market rally
Via
MarketBeat
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Top Analyst Reports For Abbott, BP & Gilead
June 21, 2024
Today's Research Daily features new research reports on 16 major stocks, including Abbott Laboratories, BP p.l.c.and Gilead Sciences, Inc., as well as two micro-cap stocks Smith-Midland Corp. and...
Via
Talk Markets
Nvidia Snaps 8-Week Winning Run, S&P 500 Marks Longest Streak Without A 2% Drop Since Great Recession, Oil Prices Stage Comeback: This Week In The Market
June 21, 2024
Stock market rally continues with new highs in S&P 500 and Nasdaq 100, driven by tech and semiconductor sectors, but concerns arise over lack of broad participation and high concentration in mega-cap...
Via
Benzinga
Topics
Economy
Stocks
Exposures
Economy
US Equities
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
June 21, 2024
Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatments.
Via
Benzinga
Why Gilead Sciences Stock Is Trading Higher Friday
June 21, 2024
On Thursday before the market opened, Gilead announced efficacy data for its possible HIV prevention drug, Lenacapavir.
Via
Benzinga
Pre-Market Movers - June 21, 2024
June 21, 2024
Sarepta jumps after announcing expanded approval of DMD drug and more news on today's top movers.
Via
Talk Markets
Gilead Sciences Stock Surges on HIV Treatment Trial Success
June 21, 2024
Gilead Sciences (NASDAQ: GILD) saw its stock jump nearly 10% yesterday after announcing groundbreaking results from its HIV treatment trial.
Via
MarketBeat
Exposures
Product Safety
Defying the Norms: 3 High P/E Stocks With Room to Run
June 21, 2024
Gilead Sciences, Crowdstrike and DataDog might be the best high P/E stocks to buy, offering substantial growth despite elevated valuations.
Via
InvestorPlace
S&P 500, Nasdaq 100 Dip From Record Highs As Investors Take Chipmaker Profits; Energy Sector Rebounds, Yields Rise: What's Driving Markets Thursday?
June 20, 2024
After the Juneteenth holiday break, Wall Street reopened with a cautious tone, as the S&P 500 and Nasdaq 100 indices declined after hitting all-time highs around midday trading in New York. This...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Gilead Flashes A Bullish Sign After HIV Drug Proves 100% Effective
June 20, 2024
The company tested its HIV prevention drug in cisgender women in Uganda and South Africa.
Via
Investor's Business Daily
Why Is Gilead Sciences Stock Trading Higher On Thursday?
June 20, 2024
Gilead Sciences announced its Phase 3 PURPOSE 1 trial results showing 100% efficacy of twice-yearly injectable lenacapavir in preventing HIV-1 in cisgender women. The trial met key efficacy endpoints,...
Via
Benzinga
KB Home Reports Upbeat Earnings, Joins Harrow, Accenture, Gilead Sciences And Other Big Stocks Moving Higher On Thursday
June 20, 2024
Via
Benzinga
Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention
June 20, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
June 20, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:KYMR),(NASDAQ:GILD),(OTCQX:RHHBY),(NASDAQ:AMGN) EQNX::TICKER_END
Via
FinancialNewsMedia
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
June 20, 2024
From
FN Media Group LLC
Via
GlobeNewswire
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
June 17, 2024
With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities.
Via
InvestorPlace
Gilead Has A Narrative-Changing Revelation For Its Weight-Loss Contender
June 17, 2024
The company tested a GLP-1 drug in monkeys. But it might not actually be an obesity treatment.
Via
Investor's Business Daily
Detailed Data From Gilead Halted Blood Cancer Drug Magrolimab Program Shows Higher Deaths And Side Effects
June 17, 2024
Gilead's recent data from two Phase 3 trials show higher adverse events and lower transplant rates in patients treated with magrolimab.
Via
Benzinga
Topics
Death
Exposures
Death
Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar
June 14, 2024
The company just unveiled preclinical results from a test of its GLP-1 weight-loss drug.
Via
Investor's Business Daily
New Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of Treatment
June 14, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
10 Health Care Stocks Whale Activity In Today's Session
June 13, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
50
51
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.